These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7952982)

  • 21. The treatment of depression with group behavioural-cognitive therapy and imipramine.
    Stravynski A; Verreault R; Gaudette G; Langlois R; Gagnier S; Larose M
    Can J Psychiatry; 1994 Sep; 39(7):387-90. PubMed ID: 7987780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators.
    Br J Psychiatry; 1992 Feb; 160():191-202; discussion 202-5. PubMed ID: 1540759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder.
    Roy-Byrne PP; Craske MG; Stein MB; Sullivan G; Bystritsky A; Katon W; Golinelli D; Sherbourne CD
    Arch Gen Psychiatry; 2005 Mar; 62(3):290-8. PubMed ID: 15753242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in appetite and weight during the pharmacological treatment of patients with panic disorder.
    Balon R; Yeragani VK; Pohl R; Merlos B; Sherwood P
    Can J Psychiatry; 1993 Feb; 38(1):19-22. PubMed ID: 8448714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of pharmacotherapist characteristics on treatment outcome in panic disorder.
    Gorman JM; Martinez JM; Goetz R; Huppert JD; Ray S; Barlow DH; Shear MK; Woods SW
    Depress Anxiety; 2003; 17(2):88-93. PubMed ID: 12621597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia.
    Bakish D; Hooper CL; Filteau MJ; Charbonneau Y; Fraser G; West DL; Thibaudeau C; Raine D
    Psychopharmacol Bull; 1996; 32(1):135-41. PubMed ID: 8927663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive behavior therapy for treatment-refractory panic disorder.
    Pollack MH; Otto MW; Kaspi SP; Hammerness PG; Rosenbaum JF
    J Clin Psychiatry; 1994 May; 55(5):200-5. PubMed ID: 8071270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The sequence of improvement of the symptoms encountered in patients with panic disorder.
    Rifkin A
    Compr Psychiatry; 1991; 32(6):559-60. PubMed ID: 1778083
    [No Abstract]   [Full Text] [Related]  

  • 29. Sequential combination of imipramine and self-directed exposure in the treatment of panic disorder with agoraphobia.
    Mavissakalian M
    J Clin Psychiatry; 1990 May; 51(5):184-8. PubMed ID: 2335493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imipramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapy.
    Rynn M; García-España F; Greenblatt DJ; Mandos LA; Schweizer E; Rickels K
    J Clin Psychopharmacol; 2003 Oct; 23(5):505-8. PubMed ID: 14520129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of cognitive therapy and relaxation training for panic disorder.
    Beck JG; Stanley MA; Baldwin LE; Deagle EA; Averill PM
    J Consult Clin Psychol; 1994 Aug; 62(4):818-26. PubMed ID: 7962886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The role of psychotherapy in managing panic disorder].
    Cottraux J
    Encephale; 1996 Dec; 22 Spec No 5():54-60. PubMed ID: 9138948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcome in cognitive-behavioral treatment of panic disorder: clinical predictors and alternative strategies for assessment.
    Brown TA; Barlow DH
    J Consult Clin Psychol; 1995 Oct; 63(5):754-65. PubMed ID: 7593868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Panic disorder and agoraphobia: what is effective?].
    Bandelow B; Sievert K; Röthemeyer M; Hajak G; Broocks A; Rüther E
    Fortschr Neurol Psychiatr; 1995 Nov; 63(11):451-64. PubMed ID: 8575719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive bias in panic disorder patients and changes after cognitive-behavioral treatments.
    Westling BE; Ost LG
    Behav Res Ther; 1995 Jun; 33(5):585-8. PubMed ID: 7598682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluctuation of symptoms and social functioning in panic disorder with or without concomitant depression. A 5-year prospective follow-up.
    Albus M; Scheibe G; Scherer J
    Psychopathology; 1995; 28(5):229-34. PubMed ID: 8559945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential relapse following cognitive therapy and pharmacotherapy for depression.
    Evans MD; Hollon SD; DeRubeis RJ; Piasecki JM; Grove WM; Garvey MJ; Tuason VB
    Arch Gen Psychiatry; 1992 Oct; 49(10):802-8. PubMed ID: 1417433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Temporal patterns of change in panic disorder during cognitive behaviour therapy: an Indian study.
    Manjula M; Prasadarao PS; Kumaraiah V; Raguram R
    Behav Cogn Psychother; 2014 Sep; 42(5):513-25. PubMed ID: 23905590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The treatment of panic disorder in a clinical setting: a 12-month naturalistic study.
    Marchesi C; Ampollini P; Signifredi R; Maggini C
    Neuropsychobiology; 1997; 36(1):25-31. PubMed ID: 9211441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EMDR for panic disorder with agoraphobia: comparison with waiting list and credible attention-placebo control conditions.
    Goldstein AJ; de Beurs E; Chambless DL; Wilson KA
    J Consult Clin Psychol; 2000 Dec; 68(6):947-56. PubMed ID: 11142547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.